Brief: Actinium Announces Positive Interim Results From Iomab-B Pivotal Phase 3 Sierra Trial At 75% Of Total Patient Enrollment

Actinium Pharmaceuticals

07/12/2020 13:50

Dec 7 (Reuters) - Actinium Pharmaceuticals Inc  ATNM.A :
    * ACTINIUM ANNOUNCES POSITIVE INTERIM RESULTS FROM IOMAB-B
PIVOTAL
PHASE 3 SIERRA TRIAL AT 75% OF TOTAL PATIENT ENROLLMENT AT THE
62ND AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
    * ACTINIUM - 100% (49/49) OF PATIENTS RECEIVING A
THERAPEUTIC DOSE
OF IOMAB-B IN SIERRA HAVE SUCCESSFULLY PROCEEDED TO BONE MARROW
TRANSPLANT
    * ACTINIUM PHARMACEUTICALS INC - IN TOTAL, 78% (88/113) OF
PATIENTS ENROLLED ON SIERRA TRIAL WERE ABLE TO RECEIVE A BMT

Source text for Eikon:  ID:nPn47Vbdba 
Further company coverage:  ATNM.A 

 ((Reuters.Briefs@thomsonreuters.com;))